NDAORALSUSPENSIONPriority Review
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
5/8 — Partial
Priority Review
ZTALMY (ganaxolone) by Marinus Pharmaceuticals is gaba a receptor positive modulators [moa]. First approved in 2022.
Drug data last refreshed 1m ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZTALMY (ganaxolone) is an oral neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors, enhancing GABAergic inhibitory neurotransmission in the central nervous system. Approved in March 2022, it is indicated for seizure disorders in pediatric and adult patients. The drug represents a novel mechanism class within antiepileptic therapy, offering an alternative to traditional anticonvulsants.
$0.953MPart D
Peak16.0 years to LOEEarly-stage adoption with minimal Part D volume (50 claims) suggests the brand is still penetrating a niche market; commercial teams should expect gradual growth as awareness expands among neurologists.
Mechanism of Action
GABA A Receptor Positive Modulators
Pharmacologic Class:
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
Clinical Trial Evaluating the Effects of Ganaxolone in Children With Autism
Started Jan 2027
66 enrolled
Autism in ChildrenAutistic Disorder in Children and AdolescentsAutism Spectrum Disorder
To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)
Started Mar 2024
0Refractory Status Epilepticus
Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)
Started Apr 2023
0Status Epilepticus
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
Started Apr 2020
23 enrolled
Tuberous Sclerosis
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
Started May 2019
29 enrolled
PCDH19-Related Epilepsy
Worked on ZTALMY at Marinus Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.